Jim Tananbaum is the current CEO and Founder of Foresite Capital, an organization that offers growth capital to emerging healthcare firms with transformative products and services to help them become leaders in the health sector. Under Tananbaum’s leadership, the company is recognized as a prominent investor of innovative healthcare firms. Recently, Foresite Capital named Molly He Ph.D., as a venture partner. With more than 15 years’ experience in scientific research and development, Molly is anticipated to be an invaluable resource to Foresite Capital, owing to her extensive knowledge in genomics and drug development, reports pelotontherapeutics.com. The company is based in San Francisco and has an office in New York.
Dr. Tananbaum is an established scientist and a remarkable entrepreneur with more than 20 years experience in building and growing healthcare companies. Before founding, Jim worked at numerous healthcare firms. He started off his career at GelTex Pharmaceuticals, a drug company he co- founded in 1993. GelTex introduced two drugs to market for less than $80 million, and it was later acquired at $1.6 billion. In 1997, Jim Tananbaum founded Theravance, a biopharmaceutical company which currently has a market capitalization of $3.5 billion. As an investor, he was a partner at Sierra Ventures, where he played a key role in establishing the company’s healthcare services investment practice. Jim was also a founding partner of Prospect Venture Partners II and III where he held senior management positions for nine years, since 2001. In 2010, he left and founded Foresite Capital, where he currently serves as CEO. Throughout his career, Dr. Jim Tananbaum has led several investments such as Amerigroup, Amira Pharmaceuticals and Jazz Pharmaceuticals among others. Jim holds a Doctor of Medicine from Harvard Medical School, Master of Science from MIT, an M.B.A from Harvard Business and a B.S. and B.S.E.E from Yale University. He has served in visiting committees and advisory boards to Yale’s President Advisory Counsel as well as the Harvard-MIT HST program
Dr. Tananbaum has been severally recognized for his successful investment ventures. He was recently named to Forbes’ List of Top Tech Investors for the third year in a row. The Forbes Midas List recognizes the top 100 futuristic investors who make strategic decisions in their tech firms and create excellent returns for their investors. This year, Tananbaum ranked at number 52.
Jim Tananbaum is a brilliant manager, visionary leader and an established entreprenuer. He has made a significant impact in all the companies he has worked in, and he continues to steer Foresite Capital to great heights through his vast experience and innovative skills.